The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.

PubWeight™: 0.90‹?›

🔗 View Article (PMC 4658189)

Published in PLoS Med on November 24, 2015

Authors

Arin Dutta1, Catherine Barker1, Ashley Kallarakal1

Author Affiliations

1: Palladium, Washington, District of Columbia, United States of America.

Articles cited by this

Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89

A systematic review of task- shifting for HIV treatment and care in Africa. Hum Resour Health (2010) 6.48

Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet (2012) 3.94

Rationale and uses of a public HIV drug-resistance database. J Infect Dis (2006) 2.91

Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Transm Infect (2012) 2.88

Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull World Health Organ (2009) 2.85

A call to action for comprehensive HIV services for men who have sex with men. Lancet (2012) 2.70

Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet (2010) 2.26

Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One (2011) 2.05

Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr (2012) 2.03

CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ (2011) 1.96

Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries. Pharmacoeconomics (2011) 1.89

Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS (2013) 1.73

Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia. PLoS One (2012) 1.57

Outcomes of antiretroviral treatment program in Ethiopia: retention of patients in care is a major challenge and varies across health facilities. BMC Health Serv Res (2011) 1.47

The determinants of HIV treatment costs in resource limited settings. PLoS One (2012) 1.47

The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review. Health Policy Plan (2012) 1.47

Estimated mortality of adult HIV-infected patients starting treatment with combination antiretroviral therapy. Sex Transm Infect (2012) 1.41

Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence (2011) 1.37

Estimate of HIV prevalence and number of people living with HIV in India 2008-2009. BMJ Open (2012) 1.34

Multi-country analysis of treatment costs for HIV/AIDS (MATCH): facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia. PLoS One (2014) 1.33

HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions. PLoS Med (2012) 1.29

ARVs: the next generation. Going boldly together to new frontiers of HIV treatment. Glob Health Sci Pract (2015) 1.23

Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings. Bull World Health Organ (2012) 1.21

Trials challenging HIV drug doses could usher in huge cost cuts. Nat Med (2013) 1.17

Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antivir Ther (2014) 1.17

Retention in care and outpatient costs for children receiving antiretroviral therapy in Zambia: a retrospective cohort analysis. PLoS One (2013) 1.16

Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One (2011) 1.16

Population-based monitoring of HIV drug resistance in Namibia with early warning indicators. J Acquir Immune Defic Syndr (2010) 1.15

Cost and outcomes of paediatric antiretroviral treatment in South Africa. AIDS (2013) 1.12

ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics. J Int AIDS Soc (2013) 1.07

What is the cost of providing outpatient HIV counseling and testing and antiretroviral therapy services in selected public health facilities in Nigeria? J Acquir Immune Defic Syndr (2012) 0.97

Point of Care Technologies for HIV. AIDS Res Treat (2014) 0.95

The impact and cost of the 2013 WHO recommendations on eligibility for antiretroviral therapy. AIDS (2014) 0.95

Financing essential HIV services: a new economic agenda. PLoS Med (2013) 0.95

Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. BMC Health Serv Res (2014) 0.93

Prices paid for adult and paediatric antiretroviral treatment by low- and middle-income countries in 2012: high, low or just right? Antivir Ther (2014) 0.92

How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? AIDS (2014) 0.90

The Costs of Delivering Integrated HIV and Sexual Reproductive Health Services in Limited Resource Settings. PLoS One (2015) 0.88

The cost of antiretroviral treatment service for patients with HIV/AIDS in a central outpatient clinic in Vietnam. Clinicoecon Outcomes Res (2014) 0.88

Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study. BMC Public Health (2014) 0.88

Evaluation of the Ethiopian Millennium Rural Initiative: impact on mortality and cost-effectiveness. PLoS One (2013) 0.86

Costing analysis of national HIV treatment and care program in Vietnam. J Acquir Immune Defic Syndr (2014) 0.85

A description of HIV prevalence trends in Nigeria from 2001 to 2010: what is the progress, where is the problem? Pan Afr Med J (2014) 0.82

Antiretroviral procurement and supply chain management. Antivir Ther (2014) 0.81

Trends in procurement costs for HIV commodities: a 7-year retrospective analysis of global fund data across 125 countries. J Acquir Immune Defic Syndr (2014) 0.77

Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa. J Int AIDS Soc (2014) 0.77

Superior outcomes and lower outpatient costs with scale-up of antiretroviral therapy at the GHESKIO clinic in Port-au-Prince, Haiti. J Acquir Immune Defic Syndr (2014) 0.76

Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market. Global Health (2013) 0.76